

## Kodiak Sciences to Present at Upcoming Conferences

November 8, 2021

PALO ALTO, Calif., Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:

- Jefferies London Healthcare Conference (pre-recorded fireside chat available on Thursday, November 18 at 12:00 a.m. Pacific Time)
- Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1 at 8:45 a.m. Pacific Time

A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at <http://ir.kodiak.com/> and will remain available for replay for a limited time following the events.

### About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Kodiak's ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, Kodiak's bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and Kodiak is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit [www.kodiak.com](http://www.kodiak.com).

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

 View original content: <https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301418960.html>

SOURCE Kodiak Sciences Inc.

John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, [ir@kodiak.com](mailto:ir@kodiak.com)